Understanding Amgen Inc. and Its Role in Global Drug Supply
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. With annual revenues exceeding $28 billion and a product portfolio spanning oncology, cardiovascular disease, bone health, inflammation, and metabolic disorders, Amgen's manufacturing decisions and export policies have ripple effects across global healthcare systems.
For the diabetes community specifically, Amgen's relevance has grown substantially through its biosimilar insulin programme and its acquisition of Horizon Therapeutics. Amgen manufactures Avsola (infliximab-axxq), Kanjinti (trastuzumab-anns), Mvasi (bevacizumab-awwb), and - critically for metabolic disease - has launched biosimilar insulin programs in multiple markets. The company is also the manufacturer of Repatha (evolocumab), a PCSK9 inhibitor used in diabetic patients with high cardiovascular risk.
Export bans and trade restrictions on pharmaceutical companies like Amgen can emerge from multiple directions: geopolitical sanctions, bilateral trade disputes, domestic supply priority mandates (where a government requires a manufacturer to supply its domestic market first before exporting), intellectual property enforcement actions, and quality or safety-related export holds. Understanding each category is essential for patients, pharmacists, and healthcare systems that depend on a continuous supply of Amgen's products.
The Biosimilar Insulin Landscape and Amgen's Position
Insulin access is arguably the most critical pharmaceutical supply issue for diabetics worldwide. The biosimilar insulin market has been transformative in countries where high insulin prices have historically been a life-or-death issue for uninsured or underinsured patients. Amgen's biosimilar activities in this space - particularly its collaboration with AstraZeneca and subsequent independent biosimilar programmes - make any disruption to its export capabilities directly relevant to insulin access.
In the United States, the Inflation Reduction Act of 2022 capped insulin costs at $35 per month for Medicare beneficiaries and paved the way for biosimilar insulin competition. Amgen has positioned itself as a key competitor in the biosimilar insulin market, and any export ban or trade restriction that affects its manufacturing facilities or distribution networks could have downstream consequences for insulin availability and pricing in markets that depend on Amgen-manufactured products.
It is worth distinguishing between two types of biosimilar insulin: "authorised generics" - exact copies of reference insulin products sold under different brand names by the originator company or licensor - and true biosimilars, which are independently developed and demonstrated to be highly similar to the reference product. Amgen's biosimilar insulins fall into the latter category, requiring extensive analytical, preclinical, and clinical studies to establish biosimilarity.
Trade Restrictions, Sanctions, and Export Controls: How They Affect Drug Supply
Export bans on pharmaceutical companies - including Amgen - can arise through several distinct mechanisms, each with different implications for drug availability:
US Export Administration Regulations (EAR): The US Bureau of Industry and Security (BIS) maintains an Entity List and Commerce Control List that can restrict exports to certain countries or entities. While pharmaceutical products generally benefit from humanitarian exemptions under EAR, biologics and biosimilars with dual-use potential (e.g., those derived from recombinant DNA technology) can sometimes be subject to export licence requirements in certain geopolitical contexts.
Office of Foreign Assets Control (OFAC) Sanctions: OFAC administers US economic and trade sanctions programmes. While medicines are broadly exempt from most sanctions programmes under humanitarian general licences, the complexities of financial transactions, shipping, and technology transfer can effectively restrict pharmaceutical exports to sanctioned countries even without an explicit drug export ban.
Domestic Supply Priority Orders: Under the Defence Production Act and similar legislation, the US government can direct manufacturers to prioritise domestic supply. During COVID-19, this mechanism was used extensively. A similar order applied to Amgen's products could temporarily restrict exports while domestic needs are met.
Regulatory Enforcement Actions: If an FDA inspection of an Amgen manufacturing facility identifies serious quality or safety deficiencies, the agency can issue an import alert or manufacturing pause that effectively restricts the supply of products from that facility - affecting both domestic and export supply.
Amgen's Manufacturing Footprint and Export Vulnerabilities
Amgen operates manufacturing facilities across the United States (Thousand Oaks, CA; West Greenwich, RI; Louisville, KY; Holly Springs, NC), Puerto Rico, the Netherlands (Breda), Ireland (Dun Laoghaire), Singapore, and other locations. This geographic diversification provides significant resilience against single-point disruptions but does not entirely eliminate export vulnerability.
Puerto Rico, which hosts a major pharmaceutical manufacturing hub, occupies a particularly complex position. As a US territory, Puerto Rican manufacturing is subject to US export regulations and can be affected by US sanctions policy. However, major hurricanes (Maria in 2017, Fiona in 2022) have demonstrated how natural disasters can disrupt pharmaceutical manufacturing and export supply chains with global consequences.
The Netherlands facility is subject to EU export regulations, which have generally been more permissive than US controls for humanitarian medical products. However, EU export restrictions on medicines and precursor chemicals have been invoked in specific circumstances, and any escalation of EU-US trade tensions could theoretically affect cross-border supply chains involving Amgen's European operations.
Repatha (Evolocumab) and Cardiovascular Risk in Diabetics
Amgen's Repatha (evolocumab) deserves particular attention in the diabetes context because cardiovascular disease is the leading cause of death in people with type 2 diabetes. Repatha is a PCSK9 inhibitor that dramatically lowers LDL cholesterol - typically by 50–60% on top of statin therapy - and has demonstrated a 20% reduction in major cardiovascular events in the FOURIER trial.
For diabetic patients with established cardiovascular disease or multiple risk factors, Repatha represents a potentially life-saving option when statins alone are insufficient. Any export restriction that limits access to Repatha in countries outside the US and EU would disproportionately affect diabetic populations, given their elevated cardiovascular risk burden.
It is also worth noting that the FOURIER trial raised a concerning signal: evolocumab was associated with a slightly higher rate of new-onset diabetes compared to placebo. This paradox - a drug that reduces cardiovascular risk in diabetics while possibly increasing diabetes risk in non-diabetics - illustrates the complex risk-benefit calculus that clinicians and policymakers must navigate.
The Broader Context: Pharmaceutical Export Bans and Global Health Equity
Amgen Inc. export bans must be understood within the broader context of pharmaceutical nationalism - the tendency for countries to prioritise domestic drug supply over export commitments during times of shortage or geopolitical tension. COVID-19 dramatically accelerated this trend, with multiple governments invoking emergency powers to restrict vaccine and drug exports, even when doing so violated bilateral trade agreements.
For patients in lower and middle-income countries that rely on imported biologics from Amgen and similar companies, export bans can rapidly translate into medication shortages. Unlike small-molecule drugs, which can often be manufactured by multiple generic producers simultaneously, biologics like evolocumab, insulin analogues, and monoclonal antibodies require specialised bioreactor manufacturing capabilities that cannot be easily or quickly replicated.
The World Health Organisation's TRIPS waiver discussions, ongoing debates about pharmaceutical intellectual property in trade agreements, and the push for technology transfer to lower-income countries are all responses to the structural vulnerability of global drug supply chains - of which export restrictions on companies like Amgen are a significant component.
What Patients and Healthcare Systems Can Do
While individual patients have limited control over multinational trade policy, there are practical steps that healthcare systems and individual diabetic patients can take to manage the risk of supply disruption:
Therapeutic alternatives: For most Amgen products, there are alternative medications in the same or adjacent therapeutic classes. Patients on evolocumab (Repatha) can, in consultation with their cardiologist, consider alirocumab (Praluent, Sanofi/Regeneron) as an alternative PCSK9 inhibitor. Patients on Amgen biosimilar insulins can typically be transitioned to reference insulins or biosimilars from other manufacturers.
Stockpiling policies: Hospital formularies and national health stockpile managers should consider maintaining larger buffer stocks of critical biologics manufactured by a limited number of producers, particularly those with known export risk profiles.
Diversified sourcing: Healthcare systems that rely on a single manufacturer for a critical drug class - such as insulin - should actively work to qualify multiple suppliers from different geographic regions to build supply chain resilience.
Regulatory intelligence: Patients and clinicians should monitor FDA Drug Shortages Database, the EU's EPITT shortage system, and their national medicines agency for early alerts about supply disruptions affecting Amgen products.
Conclusion: Navigating Uncertainty in Pharmaceutical Supply
Amgen Inc. export bans - whether driven by geopolitical sanctions, domestic supply priorities, or regulatory enforcement - represent a real and underappreciated risk to continuous access to important medications for people with diabetes and cardiovascular disease. The company's position as a major biosimilar producer, combined with its critical cardiovascular products like Repatha, means that disruptions to its export capacity have direct health consequences for patients worldwide.
The most effective protection is systemic: diversified manufacturing networks, robust national stockpile policies, therapeutic substitution frameworks, and diplomatic efforts to keep humanitarian drug exports insulated from geopolitical trade conflicts. Individual patients are best served by understanding their therapeutic alternatives and working with their healthcare teams to ensure that no single supply chain dependency puts their health at undue risk.
Frequently Asked Questions
What Amgen products are most relevant to diabetes patients?
Key Amgen products relevant to diabetes patients include biosimilar insulins, Repatha (evolocumab) for cardiovascular risk reduction in diabetics with high LDL, and various biologics used by diabetics with comorbid inflammatory conditions.
Can export bans on Amgen affect insulin availability?
Yes - as a manufacturer of biosimilar insulin products, any export restriction on Amgen's manufacturing facilities could reduce insulin supply in markets that rely on their products, particularly if single-supplier dependency exists.
What causes pharmaceutical export bans?
Pharmaceutical export bans can result from geopolitical sanctions (OFAC), domestic supply priority orders (Defence Production Act), FDA manufacturing enforcement actions, or bilateral trade disputes that restrict pharmaceutical shipments.
What should diabetics do if their medication is affected by an export ban?
Consult your physician about therapeutic alternatives in the same drug class, contact your pharmacist about alternative manufacturers' versions, and monitor the FDA Drug Shortages Database for real-time supply updates.